Invention Grant
- Patent Title: Heterocyclic compounds for the inhibition of PASK
-
Application No.: US16991726Application Date: 2020-08-12
-
Publication No.: US11459307B2Publication Date: 2022-10-04
- Inventor: John M. McCall , Donna L. Romero , John McKearn , Michael Clare
- Applicant: BioEnergenix LLC
- Applicant Address: US CA San Francisco
- Assignee: BioEnergenix LLC
- Current Assignee: BioEnergenix LLC
- Current Assignee Address: US CA San Francisco
- Agent Dennis A. Bennett; Brock Levin
- Main IPC: C07D241/44
- IPC: C07D241/44 ; A61K45/06 ; C07D401/04 ; C07D401/12 ; C07D403/04 ; C07D405/04 ; C07D409/04 ; C07D241/54 ; C07D403/12 ; C07D405/14 ; C07D413/04 ; C07D471/04 ; C07D401/14 ; C07D405/12
Abstract:
Disclosed herein are new heterocyclic compounds and compositions and their application as pharmaceuticals for the treatment of disease. Methods of inhibiting PAS Kinase (PASK) activity in a human or animal subject are also provided for the treatment of diseases such as diabetes mellitus.
Public/Granted literature
- US20210198216A1 HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK Public/Granted day:2021-07-01
Information query
